GB2551453B - Nanocarrier delivery system for hydrophobic substances - Google Patents

Nanocarrier delivery system for hydrophobic substances Download PDF

Info

Publication number
GB2551453B
GB2551453B GB1713495.8A GB201713495A GB2551453B GB 2551453 B GB2551453 B GB 2551453B GB 201713495 A GB201713495 A GB 201713495A GB 2551453 B GB2551453 B GB 2551453B
Authority
GB
United Kingdom
Prior art keywords
delivery system
hydrophobic substances
nanocarrier delivery
nanocarrier
hydrophobic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1713495.8A
Other versions
GB201713495D0 (en
GB2551453A (en
Inventor
Yen Fu Ju
Meam Yee Tan Doryn
Nesaretnam Kalanithi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palm Oil Research and Development Board
Original Assignee
Palm Oil Research and Development Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palm Oil Research and Development Board filed Critical Palm Oil Research and Development Board
Publication of GB201713495D0 publication Critical patent/GB201713495D0/en
Publication of GB2551453A publication Critical patent/GB2551453A/en
Application granted granted Critical
Publication of GB2551453B publication Critical patent/GB2551453B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644Transferrin, e.g. a lactoferrin or ovotransferrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1713495.8A 2015-01-23 2016-01-21 Nanocarrier delivery system for hydrophobic substances Active GB2551453B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2015700198A MY197126A (en) 2015-01-23 2015-01-23 Nanocarrier delivery system for hydrophobic substances
PCT/MY2016/050004 WO2016118001A1 (en) 2015-01-23 2016-01-21 Nanocarrier delivery system for hydrophobic substances

Publications (3)

Publication Number Publication Date
GB201713495D0 GB201713495D0 (en) 2017-10-04
GB2551453A GB2551453A (en) 2017-12-20
GB2551453B true GB2551453B (en) 2020-09-09

Family

ID=56417447

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1713495.8A Active GB2551453B (en) 2015-01-23 2016-01-21 Nanocarrier delivery system for hydrophobic substances

Country Status (5)

Country Link
CN (1) CN107427471B (en)
AU (1) AU2016209724B2 (en)
GB (1) GB2551453B (en)
MY (1) MY197126A (en)
WO (1) WO2016118001A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094625A1 (en) * 2017-11-09 2019-05-16 Nexien Biopharma, Inc. Methods and compositions for parenteral administration of cannabidiol in the treatment of convulsive disorders
EP3849515A1 (en) * 2018-09-11 2021-07-21 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
CN112180079B (en) * 2020-09-25 2024-04-19 上海睿康生物科技有限公司 Stable liposome particle and application thereof in immune turbidimetry detection
CN113318217A (en) * 2021-06-02 2021-08-31 厦门大学 BTZ-TPGS compound, nano preparation, preparation and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053407A1 (en) * 2001-12-19 2003-07-03 Research Development Foundation Liposomal delivery of vitamin e based compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569607B (en) * 2009-06-16 2011-02-16 中国药科大学 Di-demethoxycurcumin precursor liposome and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053407A1 (en) * 2001-12-19 2003-07-03 Research Development Foundation Liposomal delivery of vitamin e based compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FU J.Y et al., "Tumor Regression After Systemic Administration of Tocotrienol Entrapped in Tumor-Targeted Vesicles", Journal of Controlled Release, (20090000), vol. 140, pages 95 - 99, *
FU J.Y. et al., "Novel Tocotrienol-Entrapping Vesicles can Eradicate Solid Tumors After Intravenous Administration", Journal of Controlled Release, (20110000), vol. 154, pages 20 - 26, *
FU J.Y. et al., "Tumor-Targeted Niosome as Novel Carrier for Intravenous Administration of Tocotrienol", Asian Journal of Pharmaceutical Sciences, vol. 11, (20160000), pages 79 - 80, (20151125), *
GOPINATH D. et al., "Ascorbyl Palmitate Vesciles (Aspasomes): Formation, Characterization and Applications", International Journal of Pharmaceutics, (20040000), vol. 271, pages 95 - 113, *
VARSHOSAZ J. et al., "Niosomes of Ascorbic Acid and a-Tocopherol in the Cerebral Ishemia-Reperfusion Model in Male Rats", BioMed Research International, (20140000), vol. 2014, no. art. ID 816103, *

Also Published As

Publication number Publication date
MY197126A (en) 2023-05-26
AU2016209724A1 (en) 2017-09-14
CN107427471A (en) 2017-12-01
GB201713495D0 (en) 2017-10-04
GB2551453A (en) 2017-12-20
WO2016118001A1 (en) 2016-07-28
CN107427471B (en) 2020-07-31
AU2016209724B2 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
GB201802837D0 (en) Awrosol delivery system
ZA201807048B (en) Medical delivery system
IL250659A0 (en) Sensor systems for drug delivery devices
EP3349670A4 (en) Releasable delivery system
EP3725349C0 (en) Improved systems for medicine delivery
SG10202012083YA (en) Liquid delivery system
PT3314091T (en) Grout delivery system
HK1254624A1 (en) Delivery systems for controlled drug release
EP3283752C0 (en) Fluid delivery system
HK1250370A1 (en) Bortezomib-based delivery system
HK1251159A1 (en) Improved nanoparticle delivery systems
GB201407614D0 (en) Content delivery system
HUE057487T2 (en) Drug delivery system
GB201715590D0 (en) Delivery system
GB2559712B (en) Solid state delivery system
GB2551453B (en) Nanocarrier delivery system for hydrophobic substances
IL246874A0 (en) Drug delivery system
IL247106A0 (en) Substance delivery system
IL275664A (en) Drug delivery system
GB201517654D0 (en) Object delivery system
GB201514495D0 (en) Self-emulsifying Nanosuspensions as Drug Delivery Systems
GB2559449B (en) Hypoallergic drug delivery system
IL256994A (en) Transdermal delivery system
IL256995A (en) Transdermal delivery system
GB201721699D0 (en) Delivery system